Gout Clinical Evidence and Pipeline Refresh Surface¶
Purpose and date boundary¶
This page holds selected clinical evidence that changes Open Enzyme research decisions. It is not an exhaustive or continuously current market map. Registry status, enrollment, sponsor ownership, regulatory status, and program activity are time-sensitive; any current-state claim must carry a retrieval date and an exact source record.
Anchored precedents¶
| Program or intervention | Exact evidence | What Open Enzyme may infer | What does not transfer |
|---|---|---|---|
| ALLN-346 Study 201 | NCT04987242, ClinicalTrials.gov record retrieved 2026-07-27; status COMPLETED; record last updated 2023-06-22 |
Clinical Trial: gut-lumen enzyme delivery reached human testing; use the exact record and publication for protocol-specific findings | Another enzyme, engineered organism, dose response, chronic efficacy, or peroxide safety |
| ALLN-346 Study 202 | NCT04987294, ClinicalTrials.gov record retrieved 2026-07-27; status TERMINATED; record last updated 2023-06-23 |
Clinical Trial record: a second exact-product study exists; the record status alone does not identify biological failure | Unposted outcomes, sponsor intent, termination cause, or class-wide failure/success |
| Dapansutrile | Published Phase 2a gout study, PMID 33005902 | Clinical Trial: direct pharmacologic NLRP3 inhibition has protocol-specific human gout evidence | Efficacy of another NLRP3 compound, another route, or a combination |
Current-state claim protocol¶
Before writing “active,” “inactive,” “terminated,” “approved,” “no trials,” “no program,” “first,” “only,” or a phase label:
- Query the primary registry and regulator.
- Record the exact identifier, result URL or API record, retrieval date, and query.
- Check sponsor and publication records for discrepancies.
- State the bounded result: database, jurisdiction, query, and date.
- Route new findings to the owning mechanism page; keep compact query and failure details in the evidence-radar receipt.
An empty search is not universal absence. A dated scan cannot support a present-tense global claim after its refresh boundary.
Research conjecture — Clinical failures as exploit maps
Grounded premises: Clinical programs test exact products, routes, populations, endpoints, and time windows (Clinical Trial evidence; ClinicalTrials.gov records). Failure or termination can arise from biology, exposure, safety, endpoint choice, financing, or operations; these are not equivalent causes.
Novel leap: No direct evidence shows that systematically coding gout-program failure modes will reliably expose a tractable new mechanism or delivery route.
Why it matters: A mechanistically sound target abandoned for a product-specific delivery or business reason may reveal an exploit that a target-only literature review misses.
Discriminating observation: At each quarterly refresh, classify every material status change by documented cause, rehydrate promising cases from primary records, and test whether any cause maps to a different exact product–route configuration with a cheaper falsification gate.
Quarterly refresh outputs¶
- New or changed trial records, with exact identifiers and retrieval dates.
- Newly posted results or primary publications.
- Adverse-event signals that mention gout or hyperuricemia, separated from causality.
- Documented program failures classified by biological, exposure, safety, endpoint, operational, or financing cause.
- Candidate threads to pull, explicitly marked as hypotheses until primary evidence is reviewed.
The evidence radar owns replaceable query state. Canonical scientific interpretation belongs on the relevant wiki page. Git and the registries retain history.
This is Phase 0 research, not clinical or treatment guidance.